Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or Older

NCT05765604 is registered in ClinicalTrials.gov with WestVac Biopharma Co., Ltd. as lead sponsor.

NCT NCT05765604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05765604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or Older
Lead sponsor
WestVac Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 14, 2023
Completion date
March 30, 2024
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19